• 

  Glenmark concludes post marketing surveillance study on Favipiravir (FabiFlu) in COVID patients

  India | September 15, 2021 11:35 IST

  On June 19, 2020, Glenmark became the first company in India to receive restricted emergency use approval from India's drug regulator for Favipiravir (FabiFlu). 

• 

  Glenmark Life Sciences IPO Listing today, GMP indicated moderate listing gain

  August 06, 2021 8:03 IST

  Glenmark Life Sciences IPO Listing Date, Glenmark Life Sciences Share Price: Glenmark Life Sciences IPO GMP is currently at Rs 85.

• 

  Glenmark Life Sciences IPO share allotment status finalised, available on KFintech's website

  August 04, 2021 8:27 IST

  Glenmark Life Sciences IPO Allotment status, Glenmark IPO GMP today: Glenmark Life Sciences IPO allotment status has been finalised. Glenmark IPO allotment status is available on KFintech's website. Glenmark Life Sciences shares will be listed on the BSE and NSE on August 6. 

• 

  Glenmark IPO Allotment Date, Status: Glenmark Life Sciences IPO GMP weak; Check listing date

  August 03, 2021 18:24 IST

  Glenmark Life Sciences IPO Allotment, Glenmark Life Sciences IPO GMP Latest: Glenmark Life Sciences IPO allotment status will be available on the website of KFintech.

• 

  Glenmark Pharma gets tentative nod from USFDA for anticoagulant drug

  World | December 21, 2020 11:56 IST

  Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules.

• 

  Glenmark’s Favipiravir drug shows encouraging results in Phase 3 clinical trial

  Business | July 23, 2020 11:39 IST

  Glenmark Pharmaceuticals on Thursday announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.

• 

  FabiFlu more economical, effective treatment option for COVID-19: Glenmark

  Business | July 21, 2020 14:47 IST

  Glenmark Pharmaceuticals on Tuesday said its generic version of antiviral drug Favipiravir, FabiFlu, is more economical and effective than other drugs available in the market approved for emergency use for treatment of COVID-19. 

• 

  Glenmark Pharmaceuticals shares tumble nearly 6 per cent

  Business | July 20, 2020 12:56 IST

  Shares of Glenmark Pharmaceuticals on Monday tumbled nearly 6 per cent after India's drug regulator sought clarification from the company over its alleged "false claims" about the use of anti-viral FabiFlu on COVID-19 patients with comorbidities and also over the "pricing" of the drug.

• 

  Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID-19 fight, say medical experts

  India | June 22, 2020 23:06 IST

  With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".

• 

  Glenmark says FabiFlu reduces viral load by 4 days, treats mild to moderate COVID-19 patients

  Business | June 22, 2020 12:28 IST

  Glenmark has become the first pharmaceutical company in India to receive regulatory approval for oral antiviral favipiravir, for the treatment of mild to moderate COVID-19.

• 

  Glenmark Pharmaceuticals shares soar 20% after COVID-19 drug Favipiravir launch

  Business | June 22, 2020 11:32 IST

  Shares of Glenmark Pharmaceuticals on Monday rallied 20 per cent after the company said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.

Advertisement
• 

  Glenmark’s FabiFlu, covid medicine to treat mild to moderate coronavirus cases; price, availability

  Health | June 22, 2020 12:53 IST

  Glenmark Coronavirus medicine FabiFlu launched at Rs 103 per tablet: Glenmark's FabiFlu has been approved for coronavirus treatment in India. FabiFlu is the first oral Favipiravir-approved medication in India for the treatment of COVID-19, the company said in a statement.

• 

  FabiFlu: All you need to know about Glenmark's COVID-19 treatment medicine

  Fyi | June 21, 2020 8:05 IST

  Drug major Glenmark Pharmaceuticals has become the first Indian company to commercially launch an antiviral drug for the treatment of mild to moderate COVID-19 patients, after it received the Indian drug regulator Drug Controller General of India (DCGI) approval.

• 

  Glenmark launches COVID-19 drug after DCGI nod

  Business | June 20, 2020 21:02 IST

  Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.

• 

  Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules

  Business | June 19, 2020 10:36 IST

  Drug major Glenmark Pharmaceuticals on Friday said it has received final nod from the health regulator for Fingolimod capsules.

• 

  Glenmark shares hit 52-week low on USFDA warning letter

  Business | October 07, 2019 12:56 IST

  Shares of the drug firm fell to its 52-week low level of Rs 284.40, on the BSE, registering a decline of 9.90 per cent over its previous closing price.

• 

  Glenmark pharma receives US regulator's approval for leukemia treatment drug

  December 27, 2016 13:13 IST

  Glenmark Pharmaceuticals has been granted a final approval from the US Food and Drug Administration (USFDA) for sale of Tretinoin Capsules, used in treatment of leukemia. "Glenmark Pharmaceuticals Inc., USA has been granted final approval

• 

  High Court bars Glenmark from making anti-diabetes drugs

  India | March 20, 2015 20:16 IST

  New Delhi: The Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing, marketing or selling its anti-diabetes drugs Zita and Zita-Met, saying it has "prima facie" infringed the patent of US drug major